Ruxolitinib Cream Is Tolerable and Effective in Cutaneous GVHD

A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease.

Related Keywords

Galina Markova , ,Cellular Therapy Meetings ,Inpatient Consultative Dermatology ,Dermatology Service ,Memorial Sloan Kettering Cancer Center ,Global Assessment ,Clinical Condition ,Composite Assessment ,Index Lesion Disease Severity ,Dermtech Smart ,Cream Formulation Of Ruxolitinib ,Patients With Cutaneous Graft Versus Host Disease ,D ,Aad ,